- Home
- CHRS vs CAAS Comparison
CHRS vs CAAS Comparison
Compare CHRS & CAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CAAS
- Stock Information
- Founded
- CHRS 2010
- CAAS N/A
- Country
- CHRS United States
- CAAS China
- Employees
- CHRS N/A
- CAAS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CAAS Auto Parts:O.E.M.
- Sector
- CHRS Health Care
- CAAS Consumer Discretionary
- Exchange
- CHRS Nasdaq
- CAAS Nasdaq
- Market Cap
- CHRS 112.5M
- CAAS 125.2M
- IPO Year
- CHRS 2014
- CAAS N/A
- Fundamental
- Price
- CHRS $0.76
- CAAS $4.10
- Analyst Decision
- CHRS Strong Buy
- CAAS
- Analyst Count
- CHRS 4
- CAAS 0
- Target Price
- CHRS $5.26
- CAAS N/A
- AVG Volume (30 Days)
- CHRS 1.7M
- CAAS 24.1K
- Earning Date
- CHRS 05-12-2025
- CAAS 05-14-2025
- Dividend Yield
- CHRS N/A
- CAAS N/A
- EPS Growth
- CHRS N/A
- CAAS N/A
- EPS
- CHRS N/A
- CAAS 0.96
- Revenue
- CHRS $272,251,000.00
- CAAS $678,635,000.00
- Revenue This Year
- CHRS N/A
- CAAS N/A
- Revenue Next Year
- CHRS N/A
- CAAS N/A
- P/E Ratio
- CHRS N/A
- CAAS $4.27
- Revenue Growth
- CHRS 19.87
- CAAS 18.33
- 52 Week Low
- CHRS $0.66
- CAAS $3.34
- 52 Week High
- CHRS $2.43
- CAAS $5.37
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- CAAS 53.47
- Support Level
- CHRS $0.71
- CAAS $4.00
- Resistance Level
- CHRS $1.06
- CAAS $4.39
- Average True Range (ATR)
- CHRS 0.08
- CAAS 0.16
- MACD
- CHRS -0.03
- CAAS 0.04
- Stochastic Oscillator
- CHRS 12.44
- CAAS 52.10
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.